SAS Output

25-APR-2019 6:10

CANCER CONTROL ACCRUAL REPORT

The REPORT Procedure

Detailed and/or summarized report

Table 1

STUDY R
E
G
O
P
E
N
ARM TOTAL
REGS.
REGS.
LAST
12
Month
REGS.
LAST
6
Month
REGS.
LAST
3
Month
REGS.
LAST
30
DAYS
REGS.
LAST
7
DAYS
ADMIN
S1007-Breast,Adj,N1,Endocrine+/-Chemo 1 Y 1 Recurrence Score testing 9383 0 0 0 0 0 BREAST
        9383 0 0 0 0 0  
 
  2 Y 2 Chemo and Endocrine Therapy 2547 0 0 0 0 0  
      3 Endocrine Therapy Alone 2536 0 0 0 0 0  
        5083 0 0 0 0 0  
 
S1207-Brst,Adj,Endocrine+/-Everolimus 1 Y 1 Blinded drug + Endocrine 959 174 88 51 23 5 BREAST
      2 Blinded drug + Endocrine 963 172 92 46 23 6  
        1922 346 180 97 46 11  
 
S1316-Compar. Effectiv. Trial for MBO 1 Y 1 Randomization Surgery 12 7 5 5 2 0 SURV
      2 Randomization Non-surgical M 13 8 7 5 2 1  
      3 Patient Choice Surgery 61 16 10 7 2 0  
      4 Patient Choice Non-surgical M 100 0 0 0 0 0  
        186 31 22 17 6 1  
 
S1415CD-TrACER CSF Standing Order Intervention for FN 1 Y 1 Site assigned to Cohort 688 235 113 51 8 0 CCD
      2 Site randomized: Control 522 215 124 59 21 1  
      3 SiteRand Int Risk: CSF 962 440 258 152 56 10  
      4 SiteRand Int Risk: No CSF 764 370 204 111 33 8  
        2936 1260 699 373 118 19  
 
S1418-Breast, Adj, TNBC, MK-3475 (Pembrolizumab) 1 Y 1 Tissue for PD-L1 testing 518 314 184 100 30 5 BREAST
        518 314 184 100 30 5  
 
  2 Y 2 Observation 222 130 78 45 16 1  
      3 MK-3475 (Pembrolizumab) 217 131 77 44 14 5  
        439 261 155 89 30 6  
 
S1501-Surv, Breast Stg IV, Card Tox w/ Carvedilol 1 Y 0 Screening 102 96 54 31 9 0 SURV
        102 96 54 31 9 0  
 
  2 Y 1 Carvedilol 18 16 10 6 1 0  
      2 No prophylaxis 20 17 11 7 1 0  
      3 Observation 55 54 29 18 7 0  
        93 87 50 31 9 0  
 
S1600-Bladder,Radical Cystectomy Outcomes Nutrition 1 Y 1 Blinded Nutrition Drink 1 1 1 1 1 0 SXQOL
      2 Blinded Nutrition Drink 2 2 2 2 0 0  
        3 3 3 3 1 0  
 
S1602-Blad, HG NMIBC, TICE/Tokyo/Prime+Tokyo BCG 1 Y 1 TICE BCG 106 74 47 32 15 2 GU
      2 Tokyo-172 BCG 106 75 47 32 16 4  
      3 Prime + Tokyo-172 BCG 104 75 48 31 16 3  
        316 224 142 95 47 9  
 
S1614-HBV in Ca Pts, TAF vs SOC 1 Y   0 0 0 0 0 0 SXQOL
        0 0 0 0 0 0  
 
S1703-Met Breast, STM-monitoring v Usual Care 1 Y 0 Screening 42 42 37 29 11 1 CCD
        42 42 37 29 11 1  
 
  2 Y 1 Control (Usual Care) 4 4 4 3 2 0  
      2 Intervention (STMDDM) 5 5 5 4 2 0  
        9 9 9 7 4 0  
 
S1714-CIPN Risk Prediction Cohort Study, Taxanes 1 Y   0 0 0 0 0 0 SXQOL
        0 0 0 0 0 0  
 
S1802-Pros, Stg IV, SST +/- Surg/RT to Primary Tum 1 Y 0 Induction SST 55 55 47 26 12 2 GU
        55 55 47 26 12 2  
 
  2 Y 1 Standard Systemic Therapy Only 11 11 10 7 3 0  
      2 SST + Surgery/RT 11 11 10 6 3 1  
        22 22 20 13 6 1  
 
S1806-Blad, MIBC, ChemoRT +/- Atezolizumab 1 Y   0 0 0 0 0 0 GU
        0 0 0 0 0 0  
 
  2 Y   0 0 0 0 0 0  
        0 0 0 0 0 0  
 
S0820-PACES: ColrecStg0-3 Blind DFMO/Sulindac 0 Y 0 Pre-Registration 546 57 43 29 10 0 PREV
        546 57 43 29 10 0  
 
  1 Y 1 Blinded drug 84 25 12 5 1 0  
      2 Blinded drug 36 0 0 0 0 0  
      3 Blinded drug 35 0 0 0 0 0  
      4 Blinded drug 80 18 6 2 1 1  
        235 43 18 7 2 1  
 

25-APR-2019 6:10

CANCER CONTROL ACCRUAL REPORT

The REPORT Procedure

Detailed and/or summarized report

Table 1

Open Studies with No Registrations
S1614-HBV in Ca Pts, TAF vs SOC regtype: 1
S1714-CIPN Risk Prediction Cohort Study, Taxanes regtype: 1
S1806-Blad, MIBC, ChemoRT +/- Atezolizumab regtype: 1
S1806-Blad, MIBC, ChemoRT +/- Atezolizumab regtype: 2